Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Lymphoma, T-Cell, Peripheral 4Lymphoma 4Hematologic Neoplasms 2Recurrence 1Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Leukemia 1Bone Marrow Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 260fludarabine phosphate 163Methotrexate 124Rituximab 112Cytarabine 109Filgrastim 106fludarabine 92Busulfan 86Peripheral Blood Stem Cell Transplantation 83Etoposide 82Vincristine 80Radiotherapy 79Tacrolimus 73Mycophenolic Acid 72Antilymphocyte Serum 68Whole-Body Irradiation 66Melphalan 63Dexamethasone 63Cyclosporine 58Doxorubicin 51Prednisone 44Methylprednisolone 44Alemtuzumab 44Mercaptopurine 41Granulocyte Colony-Stimulating Factor 40pegaspargase 35Daunorubicin 34Clofarabine 33Thiotepa 31Asparaginase 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × darinaparsin × Lymphoid × Clear all
NCT00592046 2012-07-19

A Phase I Trial of ZIO-101 in Hematologic Cancers

Alaunos Therapeutics

Phase 1 Completed
12 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡